CD274 and neoplasm: On the basis of an evolving body of evidence in HNSCC and other solid tumors that suggest PD-L1 expression on tumor-infiltrating immune cells may contribute to clinical outcome,32,33 two scoring systems were used to determine PD-L1 expression: one that analyzed expression on only tumor cells and another that included both tumor and immune cells.